Larimar Therapeutics (NASDAQ: LRMR)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-23 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.490 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Larimar Therapeutics (NASDAQ: LRMR) through any online brokerage.
Other companies in Larimar Therapeutics’s space includes: Vincerx Pharma (NASDAQ:VINC), Cabaletta Bio (NASDAQ:CABA), Cellectar Biosciences (NASDAQ:CLRB), VistaGen Therapeutics (NASDAQ:VTGN) and Galera Therapeutics (NASDAQ:GRTX).
The latest price target for Larimar Therapeutics (NASDAQ: LRMR) was reported by William Blair on Tuesday, February 15, 2022. The analyst firm set a price target for 0.00 expecting LRMR to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.
The stock price for Larimar Therapeutics (NASDAQ: LRMR) is $1.94 last updated August 9, 2022, 8:00 PM UTC.
There are no upcoming dividends for Larimar Therapeutics.
Larimar Therapeutics’s Q2 earnings are confirmed for Tuesday, August 23, 2022.
There is no upcoming split for Larimar Therapeutics.
Larimar Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.